Related Experiment Videos
Methylenedioxymethamphetamine (MDMA; 'Ecstasy') suppresses antigen specific IgG2a and IFN-gamma production
T J Connor1, D B Connelly, J P Kelly
1Department of Pharmacology, National University of Ireland, Galway, Ireland. thomas.connor@nuigalway.ie
Abstract:
Methylenedioxymethiamphetamine (MDMA; "Ecstasy") is a widely abused amphetamine derivative. In the present study, we examined the effect of acute MDMA administration on an antigen specific immune response. Responsiveness to an in vivo challenge with the soluble protein antigen keyhole limpet haemocyanin (KLH) was examined in rats following MDMA administration (2.5, 5 or 10 mg/kg; i.p.). KLH-specific serum IgM concentrations were measured 7 days following challenge, and serum IgG concentrations were measured 14 days following the KLH challenge. In addition, antigen-specific IFN-gamma and IL-6 production was measured in KLH-stimulated splenocytes. MDMA did not alter the KLH-specific IgM response. In contrast, MDMA (5 and 10 mg/kg) provoked a significant suppression of KLH-specific IgG production. Thus, MDMA administration did not alter the initial generation of the antibody response but rather inhibited antibody class switching from IgM to IgG. Two pathways for the genetic switch from IgM to IgG production were investigated. One pathway requires the Th(1) type cytokine IFN-gamma to stimulate IgM-secreting cells to switch to IgG(2a)-secreting cells. Another pathway requires the Th(2) type cytokines IL-4 and IL-6 to stimulate IgM-secreting cells to switch to IgG(1)-secreting cells. IgG(1) and IgG(2a) levels were measured to determine if these two pathways were differentially affected. The results indicate that only IgG(2a) levels were decreased following MDMA administration. Furthermore, this decrease in IgG(2a) was accompanied by decreased KLH-specific IFN-gamma production 14 days post KLH administration. In conclusion, these data indicate that MDMA alters the ability to switch from IgM to IgG(2a) production, possibly by reducing IFN-gamma. Potential health consequences for MDMA users are discussed.
Insights
Methylenedioxymethiamphetamine (MDMA) suppresses the immune system by inhibiting antibody class switching. This drug impairs the switch from IgM to IgG(2a) antibodies, potentially by reducing Interferon-gamma (IFN-gamma) production.
Area of Science:
- Immunology
- Pharmacology
- Neuroscience
Background:
- Methylenedioxymethiamphetamine (MDMA), commonly known as "Ecstasy," is a frequently abused amphetamine derivative.
- Understanding the impact of recreational drug use on immune function is crucial for public health.
Purpose of the Study:
- To investigate the effects of acute MDMA administration on antigen-specific immune responses in a rat model.
- To determine if MDMA influences antibody production, specifically the class switching from IgM to IgG.
Main Methods:
- Rats were administered varying doses of MDMA (2.5, 5, or 10 mg/kg) before being challenged with keyhole limpet haemocyanin (KLH).
- KLH-specific IgM and IgG antibody levels were measured in serum.
- Antigen-specific production of Interferon-gamma (IFN-gamma) and Interleukin-6 (IL-6) was assessed in splenocytes.
Main Results:
- MDMA did not affect the initial IgM antibody response to KLH.
- A significant suppression of KLH-specific IgG production was observed at MDMA doses of 5 and 10 mg/kg.
- The decrease in IgG was primarily associated with reduced IgG(2a) levels and diminished IFN-gamma production, suggesting an impaired Th(1) immune response pathway.
Conclusions:
- MDMA administration inhibits the antibody class switch from IgM to IgG(2a), not the initial antibody generation.
- The observed immune suppression may be mediated by a reduction in IFN-gamma, a key cytokine in the Th(1) pathway.
- These findings suggest potential adverse health consequences for MDMA users related to compromised adaptive immunity.